| Popis: |
Purpose: Dry eye in Sjogren's ends up with ulcerations, infections, and even corneal perforations. Present treatments are mainly conservative. Due to the immunosuppressive effects of Tacrolimus drop and regenerative properties of platelet-rich plasma (PRP), this study aimed to evaluate the simultaneous use of these products in dry eye management.Methods: 20 cases of Sjogren's syndrome were included in this study. Patients were divided into three groups, the 'artificial tear drop,' Tacrolimus drops,' and 'Tacrolimus, and PRP drops'. The Schirmer's and TUBT tests and corneal fluorescein staining were assessed in each case following the determination of refractive errors and intraocular pressure, one week, one month, and three months after the initiation of therapy.Results: The majority of our cases were females, making up approximately 80%. Significant differences were found when assessing the level of irritation, and the results of the TUBT as well as fluorescein staining tests between the group treated with artificial teardrops and both of the other groups three months after treatment started. (P- values of 0.0005, 0.002 and 0.01, respectively) Schirmer's test, however, did not reveal significant levels (P-value = 0.5) when comparing the three treatment groups.Conclusion: Tacrolimus drop is a suitable and effective agent in severe cases of dry eye in Sjogren's syndrome, showing even more therapeutic benefits when given with PRP, based on the results of this study. Owing to this combination's increased anti-inflammatory and regenerative effects and its accelerating effects on the resolution of clinical symptoms, it can be considered superior to conventional therapies. |
